Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13206379 | 1.00 | MCHR1 (0.79) | MCHR1TDP1 | |
| SCHEMBL10082854 | 0.94 | MCHR1 (0.70) | MCHR1 | |
| SCHEMBL10082853 | 0.94 | MCHR1 (0.70) | MCHR1 | |
| SCHEMBL10082861 | 0.92 | MCHR1 (0.69) | MCHR1 | |
| SCHEMBL10083254 | 0.90 | MCHR1 (0.90) | MCHR1 | |
| SCHEMBL10083243 | 0.89 | MCHR1 (0.85) | MCHR1 | |
| SCHEMBL10083248 | 0.89 | MCHR1 (0.85) | MCHR1 | |
| SCHEMBL10083245 | 0.88 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL10082869 | 0.87 | MCHR1 (0.66) | MCHR1 | |
| SCHEMBL10083246 | 0.87 | MCHR1 (0.90) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552199-B2 | Substituted indanes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552199-B2 | Substituted indanes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-26 | — | — | US | disclosed |
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-26 | — | — | US | disclosed |
| WO-2010092154-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | MCHR1, MCHR2, IDO1 | MCHR1 1/4885TDP1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.